Johnson & Johnson MedTech
(NYSE: JNJ)
today announced the expansion of its research, development and innovation (RD&I) activities in Ireland.
The expansion comes at the company’s site in Galway, which serves as a hub for RD&I and its Neuro Thromboembolic Initiative (NTI). Its NTI focuses on understanding unmet needs in neurovascular disease and driving innovation in stroke treatment.
J&J MedTech’s Cerenovus unit develops neurovascular technologies, including stroke treatment devices. The medtech giant continues its work on stroke treatment options at its Galway center of excellence. This latest investment in Ireland follows an expansion in 2022.
According to a news release from IDA Ireland, the foreign investment arm for the Irish government, the effort enables the company to expand its stroke-specific and liquid embolic procedural R&D capabilities.
It also helps deepen the company’s engineering and scientific talent pool and accelerate the development of new treatment solutions for patients with acute ischemic and hemorrhagic stroke.
Johnson & Johnson MedTech first established its presence in Galway in 2017. Its 2022 R&D investment, which includes a state-of-the-art innovation center, was completed earlier this year. Today’s announcement also coincides with a first meeting of the company’s Neurovascular Global Scientific Advisory Board in Galway.
Commentary from Johnson & Johnson MedTech and IDA Ireland officials
Michael Gilvarry, head of R&D for J&J MedTech Neurovascular and GM of the Galway site, said:
“By expanding our remit from ischemic stroke to include chronic subdural hematoma, and other neurovascular conditions, our talented workforce in Galway is applying their scientific knowledge and engineering skills in new ways to find solutions to these life-threatening conditions. Ireland is a critical part of our global innovation network, and this investment reflects our long-term commitment to building and advancing our neurovascular capabilities in the region for the benefit of patients around the world.”
Michael Lohan, IDA Ireland CEO, said:
“Galway and the West Region has long been a cornerstone of Europe’s medical technology sector, and our ongoing partnership with Johnson & Johnson MedTech in the neurovascular space is a shining example of the region’s status as a key innovation hub. The work at the Galway site, which is closely aligned to our new strategy, Adapt Intelligently will not only create high-skilled opportunities for local talent but will also help shape the future of stroke care through cutting-edge innovation developed here in the west of Ireland.”
